← SCYNEXIS INC (SCYX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
SCYNEXIS INC (SCYX)
Pharmaceutical Preparations · market cap $46M · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
SCYNEXIS (SCYX) is a pharmaceutical company focused on antifungal therapies, trading at ~$4.68 with a market cap of ~$372M. Its pipeline centers on SCY-078 (ibrexafungerp in various formulations) across multiple Phase 3 programs targeting mycoses, vulvovaginal candidiasis, and recurrent VVC, plus an earlier-stage SCY-635 asset in hepatitis C. With $36.7M in cash and a runway of roughly 13–14 months, the company faces near-term financing pressure.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
- 2026-12-31 (est.)Phase 1imp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| SCY-078 | Phase 3 | Mycoses |
| Ibrexafungerp | Phase 3 | Candida Vulvovaginitis |
| SCY-635 | Phase 2 | Hepatitis C Infection |
Price & technical context
3-month
+21.2%
6-month
-24.4%
12-month
-12.8%
52-wk range
$3.57–$8.88
vs 50-day MA
+11.3%
vs 200-day MA
-4.9%
Realized vol
70.4%
Max drawdown
-72.6%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SCYX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.